151 related articles for article (PubMed ID: 10477903)
1. Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS), and CYFRA 21-1 in prostate cancer patients under intermittent androgen suppression therapy.
Theyer G; Dürer A; Theyer U; Haberl I; Ulsperger E; Baumgartner G; Hamilton G
Prostate; 1999 Oct; 41(2):71-7. PubMed ID: 10477903
[TBL] [Abstract][Full Text] [Related]
2. Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy.
Theyer G; Holub S; Dürer A; Andert S; Haberl I; Theyer U; Hamilton G
Br J Cancer; 1997; 75(10):1515-8. PubMed ID: 9166947
[TBL] [Abstract][Full Text] [Related]
3. Prolonged response to a single androgen suppression phase in a subpopulation of prostate cancer patients.
Theyer G; Ulsperger E; Baumgartner G; Raderer M; Hamilton G
Ann Oncol; 2000 Jul; 11(7):877-81. PubMed ID: 10997818
[TBL] [Abstract][Full Text] [Related]
4. Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS.
Mady EA
Int J Biol Markers; 2001; 16(2):130-5. PubMed ID: 11471896
[TBL] [Abstract][Full Text] [Related]
5. A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values.
Tarle M; Frković-Grazio S; Kraljić I; Kovacić K
Prostate; 1994; 24(3):143-8. PubMed ID: 7509485
[TBL] [Abstract][Full Text] [Related]
6. Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma.
Kil PJ; Goldschmidt HM; Wieggers BJ; Kariakine OB; Studer UE; Whelan P; Hetherington J; de Reijke TM; Hoekstra JW; Collette L
Eur Urol; 2003 Jan; 43(1):31-8. PubMed ID: 12507541
[TBL] [Abstract][Full Text] [Related]
7. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma.
Tai CJ; Liu FY; Liang JA; Yang SN; Tsai MH; Kao CH
Anticancer Res; 2002; 22(6B):3793-6. PubMed ID: 12552995
[TBL] [Abstract][Full Text] [Related]
8. Serum markers for monitoring of prostatic carcinoma.
Polito M; Minardi D; Recchioni A; Giannulis I; De Sio G; Muzzonigro G
Prostate; 1997 Nov; 33(3):208-16. PubMed ID: 9365550
[TBL] [Abstract][Full Text] [Related]
9. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
Pether M; Goldenberg SL; Bhagirath K; Gleave M
Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin markers in patients with prostatic diseases.
Wolff JM; Borchers H; Brehmer B; Brauers A; Jakse G
Anticancer Res; 1999; 19(4A):2649-52. PubMed ID: 10470212
[TBL] [Abstract][Full Text] [Related]
11. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?
Nisman B; Lafair J; Heching N; Lyass O; Baras M; Peretz T; Barak V
Cancer; 1998 May; 82(10):1850-9. PubMed ID: 9587116
[TBL] [Abstract][Full Text] [Related]
13. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
14. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.
Boccon-Gibod L; Albers P; Morote J; van Poppel H; de la Rosette J; Villers A; Malmberg A; Neijber A; Montorsi F
Eur Urol; 2014 Oct; 66(4):655-63. PubMed ID: 24954791
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer.
Trevisani L; Putinati S; Sartori S; Abbasciano V; Bagni B
Chest; 1996 Jan; 109(1):104-8. PubMed ID: 8549168
[TBL] [Abstract][Full Text] [Related]
16. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
Tarle M; Kovacić K; Kastelan M
Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
[TBL] [Abstract][Full Text] [Related]
17. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
[TBL] [Abstract][Full Text] [Related]
18. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.
Goldenberg SL; Bruchovsky N; Gleave ME; Sullivan LD; Akakura K
Urology; 1995 May; 45(5):839-44; discussion 844-5. PubMed ID: 7538246
[TBL] [Abstract][Full Text] [Related]
19. Serial tissue polypeptide specific antigen determination in the followup of hormone treated carcinoma of the prostate.
Kramer G; Steiner GE; Madersbacher S; Stulnig T; Lang T; Marberger M
J Urol; 1997 Oct; 158(4):1446-51. PubMed ID: 9302140
[TBL] [Abstract][Full Text] [Related]
20. A new protocol for intermittent androgen suppression therapy of prostate cancer with unstable saddle-point dynamics.
Suzuki Y; Sakai D; Nomura T; Hirata Y; Aihara K
J Theor Biol; 2014 Jun; 350():1-16. PubMed ID: 24524858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]